

Products Under Development

(As of May 12, 2005)



Main R&D Activities

Development Stage		Compound/ Code	Efficacy/ Drug Type	Origin	Description	Other Comments
Japan	Overseas					
Application (Oct. 2004)	Phase I	URITOS KRP-197 tablets	OAB treatment	Kyorin Pharmaceutical	Potent anticholinergic agent expected to reduce adverse events such as dry mouth	Phase I completed in the United Kingdom. Joint development and marketing activities in Japan planned with Ono Pharmaceutical
Application (July 2004)	—	KIPRES Fine granules (4mg) (Generic name: montelukast sodium)	Antibronchial asthma agent	Merck & Co. (U.S.)	New oral granule formulation for children from one to five years old	An additional formulation with a new dosage jointly developed with Banyu Pharmaceutical
Phase III (Oct. 2004)	—	KIPRES tablets	Antibronchial asthma agent	Merck & Co. (U.S.)	New indication for allergic rhinitis in adults. A once daily dose of this LTD4 receptor antagonist is expected to relieve symptoms of allergic rhinitis and cause less drowsiness.	An additional indication jointly developed with Banyu Pharmaceutical
Phase III (Jan. 2004)	—	PEKIRON nail lacquer	Antimycotic agent	Kyorin Pharmaceutical	First nail varnish formulation for nail mycosis in Japan	Jointly developed with Maruho
Phase II (Oct. 2004)	Phase II (Oct. 2004)	N-5984 tablets	Diabetes and obesity treatment	Nisshin Seifun Group	A potent and selective β 3-AR agonist that reduces plasma glucose, insulinemia, TG and FFA, while increasing glucose tolerance	Jointly developed with Nisshin Pharma of the Nisshin Seifun Group
Phase II	—	AS-3201 tablets	Treatment for diabetic complications	Dainippon Pharmaceutical	Controls sorbitol accumulation in cells by effectively inhibiting aldose reductase, treating diabetic neuropathy	Jointly developed with Dainippon Pharmaceutical
—	Phase II (June 2004)	KRP-101 tablets	Hyperlipidemia treatment	Kyorin Pharmaceutical	A selective PPAR α agonist that is expected to improve overall lipid profiles by reducing LDL cholesterol and neutral fats while increasing HDL cholesterol	—

Licensing and Joint Development

Product Name/ Code	Licensee/ Research Partner	Development Stage	Efficacy/Drug Type	Origin	Other Comments
To be determined	Merck & Co. (U.S.)	—	Synthetic antibacterial agent	Kyorin Pharmaceutical/ Merck & Co. (U.S.)	Jointly researched with Merck & Co., prior to an exclusive licensing agreement
Alphagan/Alphagan P	Senju Pharmaceutical	Phase I	Glaucoma treatment	Allergan (U.S.)	Licensed from Allergan with a cross-licensing agreement for gatifloxacin ophthalmic solution. Licensed to Senju Pharmaceutical in May 2004
Ketas	MediciNova (U.S.)	—	Cerebrovascular disorder treatment	Kyorin Pharmaceutical	Licensed exclusively to MediciNova to be developed, manufactured and sold as a multiple sclerosis treatment in all countries except Japan, China, South Korea and Taiwan
KCA-757	MediciNova (U.S.)	Phase II	Bronchial asthma and interstitial cystitis treatment	Kyorin Pharmaceutical	Licensed exclusively to MediciNova to be developed and sold in all countries except Japan, China, South Korea and Taiwan